ArticleScientific reports2025
Study on the synthesis, physicochemical properties and transdermal absorption of scutellarein prodrugs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this research, we aimed to improve the lipid solubility and transdermal absorbability of scutellarein through a prodrug strategy, and then improve its efficacy for treating psoriasis. Firstly, we designed and synthesized 19 prodrugs of scutellarein, including AC (alkylcarbonyl), AAC (alkylaminocarbonyl) and AOC (alkyloxycarbonyl) series. Then, we selected three prodrugs (AC-4, AAC-2 and AOC-SEC-4) with proper log P and favorable solubility for subsequent transdermal absorption study, and the results demonstrated the three prodrugs significantly improved the transdermal flux and the drug retention in the skin. Finally, compared with the parent drug, three prodrugs obviously relieved the dorsal lesions of mice with psoriasis, remarkably reduced the epidermal thickening and Ki67 positive cells. Therefore, this study successfully improved the poor transdermal absorbability of scutellarein, dramatically increased its efficacy in treating psoriasis, and provided candidate compounds for the psoriasis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.